Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Discourse and Communication for Sustainable Education ; 12(2):96-107, 2021.
Article in English | ProQuest Central | ID: covidwho-1603564

ABSTRACT

The authors of this paper applied a new approach combining text mining and principal component analysis (PCA) to objectively determine the actual state of regional COVID-19 strategy meetings and verified its utility. The authors used text mining to analyze meeting minutes and extracted words with high phase ubiquity by co-occurrence analysis. Then, they selected words symbolizing the meeting contents (“report,” “prevention,” “rules,” and “decision”) and performed PCA using the occurrence rates of these words as variables. Two principal components (PC1, PC2) were set. For PC1, we observed maximum factor loading for “decision” (0.81) and minimum for “report” (-0.72), so we considered this axis to show the “depth of meeting discussions.” For PC2, we observed maximum factor loading for “prevention” (0.81) and minimum for “rule” (-0.76). We considered this axis to show “regional infection status.” When we created a plot of all 44 meetings, Phase 1 occurred in quadrants 3 to 4 (knowledge sharing), phase 2 began in quadrant 1 (preparation for spread), and phase 3 shifted to quadrant 2 (response to spread) with significant differences between these phases. Our findings suggest that the actual state of regional COVID-19 strategy meetings could be objectively determined by using a combination of text mining and PCA.

2.
CEN Case Rep ; 2021 Nov 15.
Article in English | MEDLINE | ID: covidwho-1516934

ABSTRACT

Various new vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been rapidly developed. The new onset and recurrence of nephrotic syndrome triggered by some vaccines have been documented and several adult cases of minimal change nephrotic syndrome newly developing after SARS-CoV-2 vaccination have been reported. However, no reports of pediatric cases have been published. Indications for SARS-CoV-2 vaccines have been expanded to those as young as 12 years old and vaccination of children has just started in Japan. We encountered a 15-year-old boy without underlying disease who newly developed nephrotic syndrome after SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech). He developed eyelid edema 4 days after vaccination and peripheral edema of the lower extremities a further 4 days later. Twenty-one days after vaccination, 60 mg of oral daily prednisolone was started. He achieved complete remission in 12 days without complications such as hypertension or acute kidney injury. We clinicians should be aware of the possibility of nephrotic syndrome developing after SARS-CoV-2 vaccination, not only in adults, but also in children.

3.
Mod Rheumatol Case Rep ; 2021 Oct 09.
Article in English | MEDLINE | ID: covidwho-1462426

ABSTRACT

We report two cases recovered from COVID-19 with rheumatoid arthritis which had been in remission or low disease activity by taking calcineurin inhibitor. Both cases had moderate to severe pneumonia treated with intravenous dexamethasone or in the severe case remdesivir in addition to it. These cases suggest that the use of calcineurin inhibitor may have affected the improvement of severe pneumonia.

4.
Infect Dis Ther ; 10(4): 2489-2509, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1375855

ABSTRACT

INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded RNA virus. Favipiravir is an orally administrable antiviral drug whose mechanism of action is to selectively inhibit RNA-dependent RNA polymerase. A preliminary trial in COVID-19 patients reported significant improvements across a multitude of clinical parameters, but these findings have not been confirmed in an adequate well-controlled trial. We conducted a randomized, single-blind, placebo-controlled Phase III trial assessing the efficacy and safety of favipiravir in patients with moderate pneumonia not requiring oxygen therapy. METHODS: COVID-19 patients with moderate pneumonia (SpO2 ≥ 94%) within 10 days of onset of fever (temperature ≥ 37.5 °C) were assigned to receive either placebo or favipiravir (1800 mg twice a day on Day 1, followed by 800 mg twice a day for up to 13 days) in a ratio of 1:2. An adaptive design was used to re-estimate the sample size. The primary endpoint was a composite outcome defined as the time to improvement in temperature, oxygen saturation levels (SpO2), and findings on chest imaging, and recovery to SARS-CoV-2-negative. This endpoint was re-examined by the Central Committee under blinded conditions. RESULTS: A total of 156 patients were randomized. The median time of the primary endpoint was 11.9 days in the favipiravir group and 14.7 days in the placebo group, with a significant difference (p = 0.0136). Favipiravir-treated patients with known risk factors such as obesity or coexisting conditions provided better effects. Furthermore, patients with early-onset in the favipiravir group showed higher odds ratio. No deaths were documented. Although adverse events in the favipiravir group were predominantly transient, the incidence was significantly higher. CONCLUSIONS: The results suggested favipiravir may be one of options for moderate COVID-19 pneumonia treatment. However, the risk of adverse events, including hyperuricemia, should be carefully considered. TRIAL REGISTRATION: Clinicaltrials.jp number: JapicCTI-205238.

5.
Intern Med ; 60(2): 231-234, 2021 Jan 15.
Article in English | MEDLINE | ID: covidwho-1067518

ABSTRACT

Cancer patients are regarded as highly vulnerable to severe acute respiratory syndrome coronavirus (SARS-CoV)-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after coronavirus disease (COVID)-19. We herein report a pancreatic cancer case in which chemotherapy was able to be reinstituted after COVID-19. The patient was a 67-year-old man diagnosed with pancreatic cancer. On day 7 after first chemotherapy, he was infected with COVID-19. A SARS-CoV-2 test was negative after one month of treatment, and we reinstituted chemotherapy. The patient has received three cycles of chemotherapy without recurrence of COVID-19. It may be feasible to reinstitute chemotherapy for cancer patients after a negative SARS-CoV-2 test.


Subject(s)
Antineoplastic Agents/therapeutic use , COVID-19/diagnosis , Pancreatic Neoplasms/drug therapy , SARS-CoV-2 , Aged , COVID-19/complications , COVID-19/diagnostic imaging , Diagnosis, Differential , Drug Administration Schedule , Humans , Male , Pancreatic Neoplasms/complications , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...